AgomAb Therapeutics NV (AGMB)

AgomAb Therapeutics NV Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2019
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2019
Cash & Equivalents	221.59	86.42	171.46	122.4	27.67	7.33
Short-Term Investments	30.39	30.1	-	-	40	-
Cash & Short-Term Investments	251.98	116.51	171.46	122.4	67.67	7.33
Cash Growth	-	-32.05%	40.08%	80.88%	823.60%	2155.87%
Other Receivables	-	4.09	2.12	16.95	3.33	0.16
Receivables	-	4.09	2.12	16.95	3.33	0.16
Other Current Assets	6.5	0.64	0.27	0.12	0.09	-
Total Current Assets	258.48	121.24	173.85	139.47	71.09	7.48
Property, Plant & Equipment	1.41	1.59	1.99	1.61	0.06	-
Goodwill	8.61	8.61	8.61	8.61	8.61	-
Other Intangible Assets	20.11	20.11	20.11	20.11	20.11	-
Other Long-Term Assets	2.32	2.16	1.8	1.46	1.13	-
Total Assets	290.92	153.71	206.36	171.26	101	7.48

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2019
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2019
Accounts Payable	11.84	7.63	5.95	6.83	3.9	-
Accrued Expenses	-	2.72	2.1	1.47	0.7	-
Current Portion of Leases	0.23	0.25	0.27	0.18	0.03	-
Current Unearned Revenue	1.26	1.46	0.8	1.18	1.78	-
Other Current Liabilities	6.74	6.53	-	1.23	23.32	-
Total Current Liabilities	20.07	18.59	9.13	10.89	29.72	-
Long-Term Leases	0.91	1.01	1.27	1.44	0.04	-
Long-Term Deferred Tax Liabilities	-	-	-	-	0.62	-
Other Long-Term Liabilities	3.44	3.21	7.88	7.5	4.37	0.86
Total Liabilities	25.55	22.8	18.28	19.82	34.75	0.86

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2019
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2019
Common Stock	304.62	0.03	0.03	0.03	0.03	10.18
Retained Earnings	-212.62	-181.65	-119.1	-72.83	-61.44	-3.56
Comprehensive Income & Other	0.43	12.84	7.47	6.62	4.91	-
Total Common Equity	92.43	-168.78	-111.6	-66.19	-56.51	6.62
Shareholders' Equity	265.38	130.9	188.08	151.44	66.25	6.62
Total Liabilities & Equity	290.92	153.71	206.36	171.26	101	7.48

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2019
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2019
Total Debt	1.14	1.25	1.55	1.62	0.06	-
Net Cash (Debt)	250.84	115.26	169.91	120.78	67.61	7.33
Net Cash Growth	-	-32.17%	40.68%	78.65%	822.76%	5771.49%
Net Cash Per Share	12.15	213.00	314.00	223.20	124.94	-
Filing Date Shares Outstanding	40.76	49.25	0.54	0.54	0.54	-
Total Common Shares Outstanding	40.76	49.25	0.54	0.54	0.54	-
Working Capital	238.41	102.65	164.72	128.59	41.37	7.48
Book Value Per Share	2.27	-3.43	-206.24	-122.32	-104.43	-
Tangible Book Value	63.71	-197.5	-140.32	-94.91	-85.23	6.62
Tangible Book Value Per Share	1.56	-4.01	-259.32	-175.40	-157.50	-
Machinery	-	0.32	0.32	-	-	-
Leasehold Improvements	-	0.36	0.36	-	-	-

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Apr 23, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 28, 2026

Data Sources Report a data error